| 潘军平,蒋桂芳.解脲支原体药敏及对氟喹诺酮类药物的耐药性临床研究[J].浙江中西医结合杂志,2016,26(3): |
| 解脲支原体药敏及对氟喹诺酮类药物的耐药性临床研究 |
| Ureaplasma urealyticum;susceptibility and resistance to fluoroquinolones in clinical studies of |
| 投稿时间：2015-08-31 修订日期：2016-01-23 |
| DOI： |
| 中文关键词: 解脲支原体 氟喹诺酮类药物 耐药性 敏感性 |
| 英文关键词:Ureaplasma urealyticum Fluoroquinolones Drug resistance Sensitivit |
| 基金项目: |
|
| 摘要点击次数: 995 |
| 全文下载次数: 13 |
| 中文摘要: |
| 【】目的:探讨解脲支原体药敏及对氟喹诺酮类药物的耐药性和敏感性。方法：选取2013年4月至2014年4月收治的432例患者资料进行分析,采用药敏试剂盒对解脲支原体进行药敏试验,采用随机抽样的方法选取4株耐喹诺酮菌株,采用PCR进行扩增gyrA基因并检测其测序,采用Blast对比方法分析耐药菌株和标准菌株序列存在的差异,分析解脲支原体药敏及对氟喹诺酮类药物的耐药性和敏感性。结果：氧氟沙星耐药性为29.90%；罗红霉素耐药性为23.76%；阿奇霉素、美满霉素以及克拉霉素耐药率为15.84%；PCR扩增中分别得到大小为335bp和310bp的片段。对4株耐喹诺酮Uu进行突变分析,结果显示：2株耐喹诺酮Uu的gyrA302位碱基C-T误义突变使其编码的101位丙氨酸变为缬氨酸；1株在gyrA13位发生突变,但是氨基酸未发生改变,另外1株为突变。结论：解脲支原体对氟喹诺酮类药物产生的敏感性主要是由于gyrA基因突变引起所控氨基酸发生变化,临床用药时应该选择针对性的抗生素治疗。 |
| 英文摘要: |
| Objective: To investigate the Ureaplasma urealyticum;susceptibility and resistance to fluoroquinolones and sensitivity. Methods: 2013, 432 cases of patient data from April to April 2014 were analyzed admitted using susceptibility kitUreaplasma urealyticum;susceptibility test, using a random sampling method to select four quinolone-resistant strains were using PCR gyrA gene amplification and sequencing detected using Blast comparative analysis method and the standard strain sequence differences in the presence of drug-resistant strains, and analysis Ureaplasma urealyticum; susceptibility and resistance to fluoroquinolones and sensitivity. Results: ofloxacin resistance was 29.90%; Luo erythromycin resistance was 23.76%; azithromycin, minocycline and clarithromycin resistance rate was 15.84%; PCR amplifications were obtained and the size of 335bp 310bp fragments. For 4-quinolone resistance mutations Ureaplasma urealyticum;analysis showed: two quinolone resistance Uu of gyrA302 CT missense mutation at base encoded it becomes valine alanine 101; a mutation in gyrA13 position, but it did not change the amino acid, in addition to a mutant. Conclusion: UU susceptibility to fluoroquinolones produce is mainly due to mutations in gyrA targeted antibiotic therapy should be selected when the alleged cause amino acid changes in clinical practice. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
